Conversion

Ronald C. Petersen

doi:10.1212/wnl.67.9_suppl_3.s12

Conversion

Ronald C. Petersen

Research output: Contribution to journal › Short survey › peer-review

20 Scopus citations

Abstract

An important aspect of assessing the efficacy of the outcome of the primary and secondary treatment trials concerns the topic of conversion. That is, how does one assess an end point such as the transition from normal to mild cognitive impairment (MCI) or the progression of MCI to Alzheimer disease (AD)? These can be difficult issues, but as more is learned about the intermediate states such as MCI, criteria can be developed.

Original language	English (US)
Pages (from-to)	S12-S13
Journal	Neurology
Volume	67
Issue number	9 SUPPL. 3
DOIs	https://doi.org/10.1212/wnl.67.9_suppl_3.s12
State	Published - Nov 2006

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/wnl.67.9_suppl_3.s12

Cite this

@article{ff96e117a8a64f8cb9a381228cf169d9,

title = "Conversion",

abstract = "An important aspect of assessing the efficacy of the outcome of the primary and secondary treatment trials concerns the topic of conversion. That is, how does one assess an end point such as the transition from normal to mild cognitive impairment (MCI) or the progression of MCI to Alzheimer disease (AD)? These can be difficult issues, but as more is learned about the intermediate states such as MCI, criteria can be developed.",

author = "Petersen, {Ronald C.}",

note = "Funding Information: Publication of this supplement was supported by an educational grant from Beaufour Ipsen. ",

year = "2006",

month = nov,

doi = "10.1212/wnl.67.9_suppl_3.s12",

language = "English (US)",

volume = "67",

pages = "S12--S13",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "9 SUPPL. 3",

}

TY - JOUR

T1 - Conversion

AU - Petersen, Ronald C.

N1 - Funding Information: Publication of this supplement was supported by an educational grant from Beaufour Ipsen.

PY - 2006/11

Y1 - 2006/11

N2 - An important aspect of assessing the efficacy of the outcome of the primary and secondary treatment trials concerns the topic of conversion. That is, how does one assess an end point such as the transition from normal to mild cognitive impairment (MCI) or the progression of MCI to Alzheimer disease (AD)? These can be difficult issues, but as more is learned about the intermediate states such as MCI, criteria can be developed.

AB - An important aspect of assessing the efficacy of the outcome of the primary and secondary treatment trials concerns the topic of conversion. That is, how does one assess an end point such as the transition from normal to mild cognitive impairment (MCI) or the progression of MCI to Alzheimer disease (AD)? These can be difficult issues, but as more is learned about the intermediate states such as MCI, criteria can be developed.

UR - http://www.scopus.com/inward/record.url?scp=33750576989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750576989&partnerID=8YFLogxK

U2 - 10.1212/wnl.67.9_suppl_3.s12

DO - 10.1212/wnl.67.9_suppl_3.s12

M3 - Short survey

C2 - 17101927

AN - SCOPUS:33750576989

SN - 0028-3878

VL - 67

SP - S12-S13

JO - Neurology

JF - Neurology

IS - 9 SUPPL. 3

ER -

Conversion

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this